Chris Kuehn
Analyst · Barclays. Please go ahead
Thanks, Dave. Please turn to Slide number 10. Based on the market backdrop Dave just outlined, and the expectation for an improving pace of global vaccine production and administration we expect to deliver strong financial performance in 2021. As Mike indicated earlier, we expect to deliver strong organic financial performance with organic revenue growth between 5% and 7%, organic leverage of approximately 30% and adjusted EPS of between $5.25 and $5.45. We also expect to see about 1.5 points of revenue growth from the three channel acquisitions which Mike discussed at the outset which will carry about 5 points of operating margin and you deliver EPS accretion of about $0.05 all in total revenue growth is expected to be between 6.5% and 8.5% and EPS is expected to be between $5.30 and $5.50 which translates to a 19% to 23% earnings growth. We expect free cash flow to remain strong at equal to or greater than 100% of adjusted net income. If we project current FX rates out to the end of the year FX would likely be a tailwind albeit too early to call, given the global uncertainty and volatility. Our FX exposure is largely translational in nature and each point of revenue we translate at approximately transitional OI rates net each point from FX would translate into about $0.05 of EPS. Please go to Slide number 11. We don't provide quarterly guidance, but given the level of uncertainty and wide range of estimates across the investment community we believe it may be constructive to provide a high level outlook for the quarter, given what we see today. Based on orders, backlog, our pipeline and visibility we currently expect organic revenues to be up approximately 5% in Q1 with strong leverage of between 30% and 35%. Acquisitions are expected to add about a 1.5 of growth, and if FX hold the current rates, FX would add about another point of growth. All in total revenues are expected to be up about 7.5%. As discussed earlier, M&A carries about 5 points of operating margin in the first year after integration-related costs, and each point of FX translates at approximately operating margin rates. Combined, these will add about $0.02 of EPS in the first quarter. There are a couple of items for Q1, that I also want to highlight to help with your models. We're currently expecting corporate costs to be approximately $70 million in Q1. Q1 is primarily impacted by stock-based compensation, which is heaviest in the first quarter based on annual investing and the timing of 2021 corporate expenses, which were more heavily weighted in Q1 than in other quarters. Our transformation activities continue to drive corporate costs lower estimated at $220 million in 2021. So, Q1 has no adverse impact of the full year. However, you may want to incorporate this outlook for modeling purposes. The other item, I want to highlight is the estimated Q1 adjusted effective tax rate of approximately 15%. The Q1 tax rate is traditionally low impacted again by stock-based compensation given annual investing in Q1. The rate in Q1 2020 was roughly 12% as a reference point. The full year 2021 guidance remains 19% to 20%. So, there is no impact of the full year from a seasonally low Q1, but you may want to use this as a guide for modeling purposes. Please go to Slide number 12. As we outlined during our investor event in December by transforming Trane Technologies we initially identified $100 million of fixed cost reductions by 2021. We've exceeded our initial cost reduction expectations delivering $100 million of savings in 2020, a full year early and we expect to deliver $140 million in savings in 2021. We are now targeting and are on track to deliver $300 million of run rate savings by 2023. Please go to Slide number 13. Our balanced capital allocation strategy is focused on consistently deploying excess cash to the opportunities with the highest returns for shareholders. Despite challenging economic conditions in 2020 we continue to strengthen our core business with high levels of business reinvestment in high ROI technology innovation and operational excellence projects which are vital to our continued growth, product leadership and margin expansion. We remain committed to maintaining a strong balance sheet that provides us with continued optionality as our markets evolve. We have a longstanding commitment to a reliable, strong and growing dividend that increases at or above the rate of earnings growth over time. We continue to pursue strategic M&A and further improves long-term shareholder returns and we continue to see value and share repurchases as the stock trades below our calculated intrinsic value. All in, we expect to consistently deploy 100% of excess cash over time. Please turn to Slide 14. And I'll discuss how we deployed excess cash in 2020, and our plans for 2021. Through the third quarter of 2020 we paused on certain elements of our balanced capital allocation strategy in favor of capital preservation and optionality given the COVID-19 pandemic. However, we did not pause on paying a strong dividend, maintaining our dividend rate and paying over $500 million to shareholders during the year. We also did not pause on paying down $300 million of debt, which matured during the year consistent with expectations upon completion of the RMT. Entering during the fourth quarter, we resumed all elements of our balanced capital allocation strategy based on our strong free cash flow generation and improved visibility to our end markets from earlier in the year. On the M&A front we invested $183 million in value accretive channel acquisitions that Mike as previously discussed. We also deploy $250 million in share repurchases during the quarter and have repurchased an additional $100 million to-date in the first quarter of 2021 for a total of $350 million. Looking at 2021 as a fully reinvesting in the business we plan to continue executing our full balanced capital allocation strategy. This week, we announced that we've increased our quarterly dividend by 11% to $2.36 per share annualized, starting with the payment this March. We also announced a new $2 billion share repurchase program, which adds significant capacity to the existing authorization, which is approximately $400 million remaining. These announcements reflect our strong balance sheet and liquidity position, our commitment to deploying 100% of excess cash over time, and our continued confidence in our ability to deliver powerful free cash flow to execute our balanced capital allocation strategy. We anticipate deploying $1 billion between value accretive M&A and share repurchases. Additionally, we plan to retire $425 million in debt as it reaches maturity in 2021. As I stated earlier, all elements of our balanced capital allocation strategy are in play and we are focused on consistently deploying excess cash to the opportunities with the highest returns to the shareholders. Now I'd like to turn the call back over to Dave and Mike to cover key investor topics of Interest and to close with a summary of key points. Dave?